Published On : September 2026
A provider assuming that business model preference alone determines how a customer relationship is structured is overlooking the classification that actually shapes it first.
Within the self-retracting needle implant drug delivery market, customer type is the classification resolved first, since a specialty biotech firm without in-house device engineering gravitates toward co-development or full outsourcing, while a large pharma company with existing device capability more often licenses technology alone.
This page describes four customer types and four business models strictly as market categories.
It provides no contract value, pricing or fee guidance, and states nothing about the commercial terms of any specific relationship.
A pharma company and a specialty biotech firm pursuing the same therapeutic application can require genuinely different business model structures, despite targeting comparable formulation and delivery system outcomes.
That is why business development teams experienced in this market confirm customer type and existing in-house capability before proposing a specific engagement model.
Four customer types and four business models complete the commercial classification tracked in this report, spanning pharma companies, CDMOs and contract formulation specialists, medical device OEMs and specialty biotech firms, and licensing, contract development and manufacturing, co-development partnerships and proprietary product commercialisation.
Pharma companies account for the largest customer type category in this report by development spend, reflecting their concentration across the largest and most capitalised implant drug delivery programmes.
For providers, confirming customer type and in-house capability early is the starting point for any business model conversation, ahead of therapeutic application or formulation detail.
For developers, customer-type breadth across pharma, CDMO, OEM and biotech relationships widens the addressable share of any given provider's commercial reach.
This pattern holds across every regulatory classification this report tracks, since even a combination product programme can be licensed, co-developed or manufactured under contract depending on the sponsoring customer's own capability.
For a provider managing relationships across multiple customer types, this means a single commercial model rarely serves the full range of engagement needs without a flexible licensing, co-development and manufacturing offering behind it.
This report covers each customer type and business model as a distinct commercial category, and the sections that follow are sequenced from the customer-facing side of the market through to the underlying engagement models each customer type tends to select.
Reading customer type and business model together, rather than treating either in isolation, is the more reliable way to anticipate how a new relationship in this market is likely to be structured.
Pharma companies and specialty biotech firms form two of the four customer types tracked in this report.
Both are named here as market categories, and this page states nothing about the contract value or commercial terms either customer type typically negotiates.
Pharma companies account for the largest customer type category in this report by development spend, reflecting their concentration across the largest and most capitalised implant drug delivery programmes.
Specialty biotech firms are generally associated with earlier-stage programmes, frequently pursuing co-development partnerships rather than in-house delivery technology development.
For providers, pharma company relationships typically involve the broadest development budget of the four customer types tracked in this report.
For providers, specialty biotech firm relationships typically require more extensive co-development support, given their generally more limited in-house device and formulation capability.
Commercially, pharma companies more frequently pursue licensing of delivery technology, retaining formulation and clinical development in-house while licensing device design from a specialised provider.
Specialty biotech firms, by contrast, more frequently pursue full co-development or proprietary commercialisation support, reflecting their comparatively limited existing infrastructure.
For providers, engaging both customer types under a flexible commercial model generally widens the addressable share of implant delivery programmes across the development pipeline.
Specialty biotech firms in particular tend to revisit their business model preference as a programme advances through clinical development, often moving from a co-development arrangement toward a more proprietary structure once internal capability and funding allow it.
|
PROCUREMENT INSIGHT Specialty biotech firms evaluating a delivery technology partner generally weigh co-development support capacity as heavily as formulation science depth, since a provider able to absorb device engineering and regulatory coordination work that an emerging biotech company has not yet built in-house reduces both development timeline and capital risk for a company operating with a comparatively lean internal team. |
CDMOs and contract formulation specialists form the third customer-facing category tracked in this report, sitting on both the provider and customer side of the value chain depending on the specific relationship.
This positioning connects closely to regulatory classification pathway, since CDMOs typically carry the combination-product regulatory experience a pharma or biotech customer is contracting for.
This category is named here as a market category, and this page states nothing about the pricing or fee structure any specific CDMO charges.
CDMOs and contract formulation specialists form a fast-growing customer type category in this report, tied to continued outsourcing of combination-product development work.
For providers, CDMO relationships typically involve contract development and manufacturing business models, distinct from the licensing arrangements more common with pharma company customers.
For developers evaluating a CDMO, formulation and device-integration capability breadth is generally the first screening criterion, ahead of geographic footprint or company size.
Commercially, this category is most closely associated with combination-product and controlled-release pharmaceutical implant regulatory classification, reflecting the coordinated formulation and device review most CDMO-supported programmes require.
For providers, CDMO relationships generally involve a longer initial qualification process than a direct licensing relationship, given the additional formulation and manufacturing capability review involved.
This pattern is most visible among biologics and peptide-loaded implant programmes, where CDMO formulation expertise is frequently the deciding factor in partner selection.
For a CDMO, maintaining relationships across both device-focused partners and direct pharma customers generally provides more consistent programme volume than depending on a single relationship type.
Medical device OEMs complete the customer type dimension tracked in this report, representing a distinct commercial relationship from pharma companies, CDMOs and specialty biotech firms.
This category is named here as a market category, and this page states nothing about the device specifications or manufacturing capacity of any specific OEM.
Medical device OEMs are generally associated with the device engineering side of a combination-product programme, frequently licensing formulation technology from a pharma or CDMO partner rather than developing it in-house.
For providers, medical device OEM relationships typically involve licensing of delivery technology in the reverse direction, formulation-side capability licensed into a device-focused company.
For developers, medical device OEM partnerships are generally evaluated when a programme's primary technical gap sits on the device engineering side rather than the formulation side.
Commercially, this category is most closely associated with self-retracting needle-based implant injectors and preloaded single-use implant applicators, reflecting device OEMs' engineering focus.
For providers, OEM relationships generally involve a more device-centred regulatory pathway discussion than a CDMO or pharma company relationship, reflecting the OEM's existing device manufacturing infrastructure.
This category represents a comparatively smaller share of customer relationships in this report relative to pharma companies and CDMOs, reflecting the market's formulation-led development pattern overall.
For an OEM entering this market, partnering with an established formulation-focused CDMO is generally a faster route to a combination-product offering than building in-house formulation science from a standing start.
Licensing of delivery technology, contract development and manufacturing, co-development partnerships and proprietary product commercialisation complete the business model dimension tracked in this report.
These four models connect closely to the providers active across these customer relationships, a landscape covered in detail on that page.
All four are named here as market categories, and this page states nothing about the specific commercial terms or royalty structure any model typically carries.
Licensing of delivery technology is generally specified when a customer already holds formulation or clinical development capability and needs device technology alone.
Contract development and manufacturing is generally specified by customers, most frequently CDMOs' own pharma and biotech clients, seeking full outsourced formulation and manufacturing support.
Co-development partnerships are generally specified when both parties contribute distinct capability, most frequently a formulation-focused CDMO and a device-focused OEM working toward a shared combination-product outcome.
Proprietary product commercialisation is generally specified by the largest, most capitalised pharma companies developing and retaining full ownership of an implant delivery programme in-house.
For providers, business model flexibility across all four categories widens the addressable share of any given customer relationship, from early-stage licensing through full proprietary development support.
For developers, confirming which business model a target partner prefers early is a useful signal of how much in-house capability that partner expects the relationship to require.
Across all four models, the underlying commercial logic is the same: the party with less in-house capability in a given discipline generally accepts a more structured, longer-term engagement in exchange for access to that capability.
Pharma companies, CDMOs and contract formulation specialists, medical device OEMs and specialty biotech firms are the four customer types tracked in this report.
Licensing of delivery technology is generally specified when a customer already holds formulation or clinical development capability and needs device technology alone, while co-development partnerships involve both parties contributing distinct capability toward a shared outcome.
Medical device OEMs and CDMOs are tracked in this report as distinct customer types, generally differentiated by device engineering focus versus formulation and manufacturing focus rather than direct competition for the same relationships.
A specialty biotech firm without in-house device engineering gravitates toward co-development or full outsourcing, while a large pharma company with existing device capability more often licenses technology alone, which is why customer type is confirmed before business model.